

## NI Formulary: Chapter 6 Endocrine

Please refer to the full version of the Formulary for further advice and information.

Therapeutic Area	Drug choice
<b>Insulins</b> <b>Rapid (analogue)</b> Immediate with food	<b>Apidra®</b> <b>Fiasp®</b> <b>Humalog® (100,200)</b> <b>Novorapid®</b>
<b>Insulins</b> <b>Short</b> 15 to 30 mins before food	<b>Actrapid®</b> <b>Humulin S®</b>
<b>Insulins</b> <b>Intermediate (Isophane)</b> Same time every day	<b>Humulin I®</b> <b>Insulatard®</b>
<b>Insulins</b> <b>Long (analogue)</b> Same time every day	<b>Abasaglar®</b> <b>Lantus®</b> <b>Levemir®</b> <b>Toujeo®</b> <b>Tresiba® (100,200)</b>
<b>Insulins</b> <b>Biphasic</b> Up to 15 mins before food	<b>Humalog® Mix (25,50)</b> <b>Novomix® 30</b>
<b>Insulins</b> <b>Biphasic Isophane</b> Up to 30 mins before food	<b>Humulin® M3</b>
<b>Biguanides</b>	<b>1 Metformin tablets 500mg</b>
<b>Sulfonylureas</b>	<b>1 Gliclazide tablets 40mg, 80mg</b>
<b>Dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitors)</b>	<b>1 Sitagliptin tablets 25mg, 50mg, 100mg</b> <b>2 Linagliptin tablets 5mg</b>
<b>Glitazones (thiazolidinediones)</b>	<b>1 Pioglitazone tablets 15mg, 30mg, 45mg</b>
<b>Sodium-glucose co-transporter 2 (SGLT-2) inhibitors</b>	<b>1 Canagliflozin 100mg, 300mg tablets</b> <b>1 Dapagliflozin 10mg tablets</b> <b>1 Empagliflozin 10mg, 25mg tablets</b>
<b>GLP-1 mimetic (injectable)</b>  <b>Prescribe by brand name</b>	<b>1 Daily injection :</b> liraglutide (Diavic®) injection 6mg/mL 3ml pre-filled pens  <b>Weekly injection:</b> <b>1</b> Dulaglutide (Trulicity®) 0.75mg/0.5ml, 1.5mg/0.5ml, 3mg/0.5ml and 4.5mg/0.5ml solution for injection pre filled pens or <b>1</b> Semaglutide (Ozempic® ▼) 0.25mg/0.19ml, 0.5mg/0.37ml, 1mg/0.74ml solution for injection pre-filled pens <b>1 Oral tablets:</b> Semaglutide (Rybelsus® ▼) 3mg, 7mg 14mg tablets
<b>Treatment of hypoglycaemia</b>	<b>1 Glucose (oral) or</b> <b>1 GlucaGen® Hypokit 1mg powder and solvent for solution for injection (glucagon)</b>

## NI Formulary: Chapter 6 Endocrine

Please refer to the full version of the Formulary for further advice and information.

Therapeutic Area	Drug choice
	<ul style="list-style-type: none"> <li>① <b>Glucose intravenous infusion</b></li> </ul>
<b>Hypothyroidism</b>	<ul style="list-style-type: none"> <li>① <b>Levothyroxine</b> tablets 25micrograms, 50micrograms, 100 micrograms</li> </ul>
<b>Hyperthyroidism</b> a) Antithyroid drugs b) Beta-blockers	<ul style="list-style-type: none"> <li>① <b>Carbimazole</b> tablets 5mg, 20mg <b>To be initiated on specialist advice</b></li> <li>① <b>Propranolol</b> tablets 10mg, 40mg</li> <li>① <b>Propranolol MR capsules</b> 80mg, 160mg</li> </ul>
<b>Corticosteroids</b> a) Replacement therapy	<p style="text-align: center;"><u>Replacement therapy (mineralocorticoid)</u></p> <ul style="list-style-type: none"> <li>① <b>Fludrocortisone</b> tablets 100micrograms</li> </ul> <p style="text-align: center;"><u>Glucocorticoid therapy</u></p> <ul style="list-style-type: none"> <li><b>Hydrocortisone</b> tablets 10mg</li> </ul>
b) Glucocorticoid therapy	<ul style="list-style-type: none"> <li>① <b>Prednisolone</b> tablets 1mg, 5mg or</li> <li>① <b>Dexamethasone</b> tablets 500micrograms, 2mg; injection 3.8mg/mL; injection 3.3mg/mL or</li> <li>① <b>Hydrocortisone</b> sodium succinate 100mg powder and solvent for solution for injection vials or</li> <li>① <b>Methylprednisolone</b> tablets 2mg, 4mg, 16mg, 100mg</li> <li>① <b>Methylprednisolone sodium succinate (Solu-Medrone®)</b> powder and solvent for injection vials 40mg, 125mg, 500mg, 1g</li> <li>① Intramuscular depot: <b>Methylprednisolone acetate</b> (Depo-Medrone®) suspension for injection vials 40mg/mL, 80mg/2mL, 120mg/3mL</li> </ul>
<b>HRT for menopausal symptoms</b> a) Women who have not had a hysterectomy	<ul style="list-style-type: none"> <li>① <u>Sequential combined (oral)</u> <b>Elleste-Duet®</b> 1mg, 2mg tablets (estradiol and norethisterone) or <b>Femoston®</b> 1/10, 2/10 tablets (estradiol and dydrogesterone)</li> <li>① <u>Sequential combined (transdermal)</u> <b>Evorel® Sequi</b> patches: (combination pack of 4 Evorel® 50 patches [estradiol 50micrograms/24hours] and 4 Evorel® Conti patches [estradiol 50micrograms/24hours]) and norethisterone acetate 170micrograms/24hours)</li> <li><u>Continuous combined (oral)</u></li> <li>① <b>Bijuve®</b> 1mg/100mg capsules ( estradiol 1mg and progesterone 100mg)</li> <li>① <b>Femoston® conti</b> 0.5mg/2.5mg tablets; 1mg/5mg tablets (estradiol and dydrogesterone)</li> <li>① <b>Indivina®</b> 1mg/2.5mg tablets;1mg/5mg tablets; 2mg/5mg tablets (estradiol and medroxyprogesterone acetate) <i>Note: only licensed when LMP occurred over 3 years previously</i></li> </ul>

## NI Formulary: Chapter 6 Endocrine

Please refer to the full version of the Formulary for further advice and information.

Therapeutic Area	Drug choice
	<ul style="list-style-type: none"> <li>① <b>Kliofem</b><sup>®</sup> tablets (estradiol 2mg and norethisterone 1mg)</li> <li>① <b>Kliovance</b><sup>®</sup> tablets (estradiol 1mg and norethisterone 500micrograms) <u>Continuous combined (transdermal)</u></li> <li>① <b>Evorel</b><sup>®</sup> <b>Conti patches</b> (estradiol 50micrograms/24hours and norethisterone 170micrograms/24hours (matrix patch))</li> </ul>
<b>b) Women who have had a hysterectomy or who have a Mirena<sup>®</sup> Intra Uterine System (IUS) in situ for &lt; 5 years</b>	<ul style="list-style-type: none"> <li><u>Unopposed oestrogens (oral)</u></li> <li>① <b>Elleste-Solo</b><sup>®</sup> 1mg, 2mg (estradiol) tablets or <b>Zumenon</b><sup>®</sup> 1mg, 2mg (estradiol) tablets</li> <li><u>Unopposed oestrogens (transdermal)</u></li> <li>① <b>Evorel</b><sup>®</sup> patches 50micrograms (or 25micrograms, 75micrograms, 100micrograms/24 hours) (estradiol)</li> <li><u>Unopposed oestrogens spray</u></li> <li>① <b>Lenzetto</b><sup>®</sup> 1.53mg/dose transdermal spray</li> <li><u>Unopposed oestrogens gel</u></li> <li>① <b>Oestrogel</b><sup>®</sup> 0.06% gel or</li> <li>① <b>Sandrena</b><sup>®</sup> gel sachets 500mcg, 1mg</li> </ul>
<b>Drugs for the treatment and management of Osteoporosis</b> <b>(a) Calcium and Vitamin D</b>	<ul style="list-style-type: none"> <li>① <b>Adcal-D3</b><sup>®</sup> Caplets (750mg/200IU) or</li> <li>① <b>Accrete D3</b><sup>®</sup> film-coated tablets (600mg/400IU) or</li> <li>① <b>Accrete D3</b><sup>®</sup> One a Day Chewable Tablets (1000 mg / 880 IU)</li> <li>② <b>Adcal-D3</b><sup>®</sup> Dissolve effervescent tablets (1500mg /400IU) <i>Reserve for swallowing difficulties</i></li> </ul>
<b>(b) bisphosphonates</b>	<ul style="list-style-type: none"> <li>① <b>Alendronic acid</b> tablets 70mg or</li> <li>① <b>Risedronate sodium</b> tablets 35mg</li> </ul>
<b>Acromegaly</b>	The primary treatment of acromegaly is usually pituitary surgery. Management and treatment requires specialist involvement. Please refer to 'Prescribing Notes' in full version of formulary.